Notice to 340B-eligible providers
Reporting 340B modifiers on drug claims
To support accurate claim adjudication and timely processing, Geisinger Health Plan (GHP) asks network providers participating in the 340B Drug Pricing Program to report the appropriate 340B modifier on applicable claims for drugs acquired through the program. This applies to professional and outpatient facility claims.
Network providers that participate in the 340B Drug Pricing Program should include the appropriate 340B modifier on claims for drugs acquired through the program.
Report the applicable 340B modifier on claims for 340B-acquired drugs administered to:
- Geisinger Gold (Medicare Advantage) members
- All Geisinger Health Plan members, regardless of line of business or plan type
The appropriate modifier is TB – drug or biological acquired with a 340B Drug Pricing Program discount and reported for informational purposes.
For dates of service on or after Jan. 1, 2025, providers and suppliers participating in the 340B Drug Pricing Program should report modifier TB on applicable claim lines for separately payable Medicare Part B drugs and biologicals acquired through the program. CMS discontinued use of modifier JG for 340B reporting effective Jan. 1, 2025.
Including the TB modifier on applicable claims helps with:
- Accurate coding and claim adjudication
- Proper identification of 340B-acquired drugs
- Timely claims processing
- Alignment with applicable billing and reporting requirements
Review your billing processes and work with coding, pharmacy, billing and revenue cycle teams to ensure the appropriate modifier is included whenever a 340B-acquired drug is billed.
Claims submitted without the applicable 340B modifier may require additional review and could be delayed.
Questions about your claims?
Call 844-GHP-PROV (844-447-7768).
Other questions? See who to call to find the right contact quickly.